UDP-glucose 4-epimerase (GALE) (GALE)

UDP-glucose 4-epimerase (GALE) is a vital enzyme in the Leloir pathway, responsible for the reversible conversion of UDP-galactose to UDP-glucose [1]. It also plays a critical role in the interconversion of UDP-N-acetylgalactosamine and UDP-N-acetylglucosamine, which are essential for the synthesis of glycoproteins and glycolipids [2]. Mutations in the GALE gene result in Type III galactosemia, a metabolic disorder that can manifest as a benign peripheral form or a severe generalized form affecting multiple organs [3]. In the field of drug discovery, GALE is identified as a promising therapeutic target for treating infections caused by pathogens such as Trypanosoma brucei and Mycobacterium tuberculosis, which rely on the enzyme for structural integrity [4]. While no FDA-approved drugs currently target GALE, research is ongoing to develop selective inhibitors for antimicrobial applications [5]. Understanding GALE's dual substrate specificity is crucial for both managing metabolic diseases and designing effective therapeutic interventions [1, 3].

Other names

UDP-galactose 4-epimeraseGalactowaldenaseUDP-Glc 4-epimeraseUridine diphosphate glucose 4-epimerase

Competitive inhibition of the enzyme's active site, preventing the interconversion of UDP-sugars, thereby disrupting cell wall synthesis in pathogens or metabolic flux in humans.